Low Adoption Barrier BioProtonics offers a software-only MRI texture analysis solution that adds a minimal workflow change and no expensive hardware. The radiology teams can implement it with a small time investment, making it attractive for hospitals, imaging centers, and academic radiology labs seeking a low-risk diagnostic enhancement.

Clinical Validation Partners The 2019 collaboration to validate µTexture demonstrates clinical credibility. Target academic medical centers, imaging departments, and research CROs to formalize pilots and publish results that accelerate adoption and procurement discussions.

Biomarker Potential µTexture targets micron-scale tissue texture changes as early disease indicators, aligning with pharma and biotech needs for monitoring therapeutic response. Pursue partnerships with pharmaceutical companies, CROs, and contract imaging labs to explore companion diagnostics or biomarker studies.

Data and Workflow The solution integrates with existing MRI workflows and relies on cloud and database technologies. Offer bundled data management, analytics dashboards, and secure storage to imaging centers and hospitals seeking end-to-end results reporting and easier integration with PACS or EMR systems.

Strategic Partnerships As a small, specialized player with solid funding and revenue, BioProtonics can scale via OEM or reseller partnerships with MRI vendors and regional distributors. Focus on California and West Coast networks, mid-size hospitals, and imaging centers with active research programs; provide a partner program with enablement and co-marketing to accelerate sales.